Heart disease prevention drug fails at final hurdle

episode

Health Report - Separate stories podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Full Show — September 22, 2026 2h 46m · 22 Sep 2026 · Rahimi & Grote Show

PDB Afternoon Bulletin | September 22nd, 2026: Tehran Offers To Reopen Hormuz & North Korea’s New Weapon 15 min · 22 Sep 2026 · The President's Daily Brief

US hits out at Aus opt-out laws + The Houthis vs Saudi Arabia explained 28 min · 22 Sep 2026 · The Briefing

Bears quarterback Tyson Bagent lands in concussion protocol (Hour 4) 40 min · 22 Sep 2026 · Rahimi & Grote Show

TAFS Unplugged: Iceage 14 min · 22 Sep 2026 · The Adam Friedland Show

'Lanterns' Episode 6 Deep Dive | House of R 1h 41m · 22 Sep 2026 · House of R

Report any issue

Source

Recorded11 Sep 2026

Publisherabc.net.au ↗

Handlerec:20350758

Show notes

The pharmaceutical company closest to getting a drug to market to reduce Lipoprotein (a) levels announced that while it reduces levels of these molecules, that didn’t translate into fewer cardiovascular events. What does this mean for those with high Lp (a)?Guest/sDr Nelson Wang, cardiologist and senior research fellow, George Institute of Public Health ReferencesNovartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in